MarketCap
Facebook
X
TelegramQuarterly report 2026-Q2
added 05-15-2026
CEL-SCI Corporation Operating Cash Flow 2011-2026 | CVM
Annual Operating Cash Flow CEL-SCI Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.1 M | -18.8 M | -22.8 M | -18.2 M | -18.8 M | -15.3 M | -16.3 M | -13.4 M | -13.8 M | -23.1 M | -23.8 M | -22.9 M | -13.5 M | -12.2 M | -22.6 M | -12.8 M | -6.51 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.51 M | -23.8 M | -17.2 M |
Quarterly Operating Cash Flow CEL-SCI Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.04 M | -4.02 M | -4.02 M | - | - | - | -4.14 M | - | - | - | -4.89 M | - | - | - | -4.67 M | -13.3 M | - | - | -4.81 M | -14 M | -8.78 M | - | -3.83 M | -11.7 M | -7.99 M | -3.83 M | -4.1 M | -12.4 M | -7.79 M | -4.1 M | -4.16 M | -9.14 M | -6.37 M | -4.16 M | -2.61 M | -10.4 M | -7.23 M | -2.61 M | -4.24 M | -16.2 M | -10.8 M | -4.24 M | -5.84 M | -18.5 M | -12.2 M | -5.84 M | -5.44 M | -17.2 M | -11.2 M | -5.44 M | -5.92 M | -10.1 M | -6.67 M | -5.92 M | -2.99 M | -8.92 M | -5.79 M | -2.99 M | -2.61 M | -17.7 M | -10.5 M | -2.61 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.61 M | -18.5 M | -7.46 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 35.0 | 1.6 % | $ 942 M | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 22.0 | 8.32 % | $ 285 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
456 M | $ 90.93 | 0.63 % | $ 22 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.65 | 1.85 % | $ 439 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
902 M | $ 8.11 | -0.98 % | $ 5.51 B |  Spain |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Heron Therapeutics
HRTX
|
-27.6 M | $ 0.87 | 3.09 % | $ 145 M | USA |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.61 | -3.51 % | $ 244 M | Israel |
 |
Anika Therapeutics
ANIK
|
11.2 M | $ 15.02 | -0.79 % | $ 215 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Incyte Corporation
INCY
|
1.41 B | $ 97.41 | 0.34 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-269 M | $ 75.78 | 0.96 % | $ 12.1 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.44 | -0.58 % | $ 5.66 M | Israel |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.57 | 3.97 % | $ 184 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-93.6 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 21.01 | 2.64 % | $ 2.67 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |